C. Fabron

Publications9
h-index2
Citations11
Highly Influential Citations0
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • Z. Younossi
  • 1,026 Publications, 51,432 Citations
  • M. Rutten-van Mölken
  • 169 Publications, 9,921 Citations
  • L. Henry
  • 172 Publications, 6,749 Citations
  • L. Groenke
  • 66 Publications, 1,072 Citations
  • Publications
  • Influence
NASH/NAFLD patients with end stage liver disease experienced high inpatient hospitalization costs and substantial disease progression: Results of a French national database on hospital care analysis
  • 2
NAFLD/NASH patients with compensated cirrhosis (CC) had a high prevalence of comorbidities, substantial liver disease progression, and increased annual number of hospitalizations and associated costs…
  • 2
Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results
Purpose Combinations of long-acting bronchodilators are recommended to reduce the rate of COPD exacerbations. Evidence from the DYNAGITO trial showed that the fixed-dose combination of tiotropium +… Expand
  • 3
  • PDF
Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database
Background Nonalcoholic fatty liver disease (NAFLD) has reached high prevalence, paralleling the obesity pandemic. The aggressive form of the disease, nonalcoholic steatohepatitis (NASH), is… Expand
  • 2
Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results
  • 1
THU-299-Increased risk of mortality with liver disease progression in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients: An analysis of French national hospital care
  • 1
Conséquences économiques du suivi biologique et des complications médicales en lien avec l’utilisation des anticoagulants injectables en France
Resume Objectif Determiner la frequence du suivi plaquettaire et les risques hemorragiques associes a l’usage des anticoagulants injectables en vie reelle et estimer les couts associes. Methode Une… Expand
[Economic consequences of biological monitoring and medical complications of injectable anticoagulants in France].
AIM To assess the frequency of platelet monitoring and bleeding risks associated with the use of injectable anticoagulants in a real life setting and to estimate the associated costs. METHOD An… Expand
PRS49 - COST-EFFECTIVENESS OF THE FIXED-DOSE COMBINATION TIOTROPIUM + OLODATEROL VERSUS TIOTROPIUM BASED ON THE DYNAGITO TRIAL RESULTS IN FRANCE